Predicting fibrosis progression in non-alcoholic fatty liver disease patients using the FAST Score: A paired biopsy study.

Autor:	Sariyar N; Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkiye., Kani HT; Department of Gastroenterology, Marmara University School of Medicine, Istanbul, Turkiye., Celikel CA; Department of Pathology, Marmara University School of Medicine, Istanbul, Turkiye., Yilmaz Y; Liver Research Unit, Institute of Gastroenterology, Marmara University, Istanbul, Turkiye.; Department of Gastroenterology, Recep Tayyip Erdogan University School of Medicine, Rize, Turkiye.
Jazyk:	angličtina
Zdroj:	Hepatology forum [Hepatol Forum] 2024 Jan 16; Vol. 5 (1), pp. 33-36. Date of Electronic Publication: 2024 Jan 16 (Print Publication: 2024).
DOI:	10.14744/hf.2023.2023.0021
Abstrakt:	Background and Aim: This study aimed to investigate the predictive value of various non-invasive scores for identifying the progression of hepatic fibrosis over time in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Materials and Methods: We examined 69 patients with NAFLD who had undergone two liver biopsies at an average interval of 21.3±9.7 months. Progression and regression of fibrosis were defined as an increase or decrease of at least one stage in fibrosis between the initial and follow-up biopsies, respectively. The Fibrosis-4 Index (FIB-4), NAFLD Fibrosis Score (NFS), Agile 3+, Agile 4, and FibroScan-AST (FAST) scores were calculated at the initial biopsy. Results: Comparison of paired biopsies revealed that 45% of participants (n=31) exhibited no change in fibrosis stages, 26% (n=18) experienced progression, and 29% (n=20) demonstrated regression. Multivariable logistic regression analysis identified the FAST score as the only independent predictor of progressive fibrosis, with the odds increasing by 19% (95% CI: 8-38%, p<0.05) for each unit increase in the FAST score at the initial biopsy. No independent predictors for fibrosis regression were identified. Conclusion: Higher baseline FAST scores were associated with an increased likelihood of fibrosis progression, independent of other variables. Thus, the FAST score could serve as both a diagnostic and prognostic tool for fibrosis in patients with NAFLD. Competing Interests: YY has received consultancy fees, speaker honoraria, and/or participated in clinical trials sponsored by Zydus, Cymabay, Novo Nordisk, and Echosens. HTK has received honoraria as a speaker on behalf of AbbVie. The other contributing authors have no competing interests to declare. (© Copyright 2024 by Hepatology Forum.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu